rpl-31 Antibody

What is RPL31 and why is it significant in cellular research?

RPL31 is a component of the 60S large ribosomal subunit encoded by the RPL31 gene. It functions as an important constituent of the peptidyltransferase center, the catalytic core responsible for peptide bond formation during protein synthesis . As part of the large ribonucleoprotein complex that synthesizes proteins in the cell, RPL31 plays a fundamental role in translation, making it relevant for studies in both normal cellular processes and disease states . Its relatively small size (approximately 14 kDa) and association with essential cellular machinery make it an intriguing subject for ribosomal assembly and function research .

What applications are RPL31 antibodies validated for?

RPL31 antibodies have been validated for multiple experimental applications across various research contexts. Based on current data, RPL31 antibodies can be reliably used for:

Different antibodies may exhibit varying performance across these applications, so researchers should consult specific product documentation for optimal results .

How do I select the appropriate RPL31 antibody for my specific research needs?

When selecting an RPL31 antibody, consider the following technical parameters:

• Epitope specificity: Different antibodies target distinct regions of RPL31. For example, some antibodies target amino acids 24-51 in the central region, while others target amino acids 5-105 or 36-125 . Choose an epitope that aligns with your experimental goals, especially if studying specific domains.

• Species reactivity: Verify the antibody's reactivity with your experimental model. Most commercial RPL31 antibodies react with human samples, while some also cross-react with mouse and rat samples . For evolutionary studies, consider antibodies with broader cross-reactivity.

• Validated applications: Ensure the antibody is validated for your intended application. Review product-specific data showing actual performance in applications like Western blotting or immunofluorescence .

• Clonality: Most available RPL31 antibodies are polyclonal, which offers advantages in signal amplification but may increase background. Select based on your sensitivity and specificity requirements .

What are the recommended dilutions and protocols for Western blotting with RPL31 antibodies?

For optimal Western blot detection of RPL31:

• Sample preparation: Use standard lysis buffers containing protease inhibitors. RPL31 has been successfully detected in various human cell lines including HEK-293T, A431, HeLa, and HepG2, as well as mouse liver tissue and NIH/3T3 cells .

• Gel selection: Use 15% SDS-PAGE gels to achieve better separation of the relatively small RPL31 protein (14 kDa) .

• Protein loading: Load approximately 30 μg of total protein per lane, based on published protocols .

• Antibody dilution: Typical working dilutions range from 1:500 to 1:1000 for most RPL31 antibodies in Western blotting applications .

• Expected result: The predicted band size is 14 kDa, which has been consistently observed across multiple antibodies and sample types .

• Positive controls: HepG2, HEK-293T, and HeLa cells have been validated as positive controls for RPL31 expression .

How can I optimize immunofluorescence detection of RPL31?

For immunofluorescence/immunocytochemistry applications with RPL31 antibodies:

• Cell fixation: Standard paraformaldehyde fixation (4%) works well for RPL31 detection. Consider methanol fixation as an alternative if initial results are suboptimal.

• Antibody dilution: Start with a dilution range of 1:50 to 1:500 as recommended for most RPL31 antibodies .

• Localization pattern: Expect predominantly cytoplasmic staining with potential nucleolar enrichment, consistent with ribosomal localization .

• Controls: Include a primary antibody omission control and consider a known RPL31-expressing cell line such as HepG2 as a positive control .

• Co-staining: Consider co-staining with nucleolar markers to confirm the expected subcellular localization pattern of this ribosomal protein.

What troubleshooting approaches should I consider if RPL31 detection fails?

When troubleshooting issues with RPL31 antibody experiments:

• For weak or absent signal:

  • Decrease antibody dilution (use more concentrated antibody)

  • Increase protein loading for Western blots

  • Extend primary antibody incubation time

  • Consider sample preparation issues that might affect protein extraction

  • Verify that your experimental model expresses detectable levels of RPL31

• For non-specific binding or high background:

  • Increase blocking time and concentration

  • Use more stringent washing conditions

  • Try a different antibody targeting an alternative epitope of RPL31

  • Optimize secondary antibody concentration

• For inconsistent results:

  • Standardize cell culture conditions (RPL31 expression may vary with cell density)

  • Use consistent lysis and extraction protocols

  • Include appropriate positive controls like HepG2 or HeLa cells

How can RPL31 antibodies be used to investigate ribosome biogenesis and assembly?

RPL31 antibodies can provide valuable insights into ribosome biogenesis through several advanced approaches:

• Immunoprecipitation studies: Use RPL31 antibodies to pull down associated ribosomal components during various stages of ribosome assembly. This can help identify temporal assembly patterns and associated factors.

• Subcellular fractionation: Combine with nucleolar, nucleoplasmic, and cytoplasmic fractionation to track RPL31 incorporation into pre-ribosomal particles during biogenesis.

• Stress response studies: Monitor changes in RPL31 localization and incorporation into ribosomes under conditions that perturb ribosome assembly, such as nucleolar stress or transcriptional inhibitors.

• Co-localization analysis: Perform co-immunofluorescence with markers of different ribosome assembly compartments to visualize the progression of RPL31 through the assembly pathway.

• Quantitative proteomics: Use RPL31 antibodies for immunoprecipitation followed by mass spectrometry to identify stage-specific interacting partners during ribosome formation.

What is known about RPL31's potential role in cancer, and how can antibodies help investigate this?

Research has revealed intriguing connections between RPL31 and cancer biology that can be further explored using RPL31 antibodies:

• Anticancer properties: Studies have demonstrated that recombinant RPL31 protein can inhibit the growth of human cancer cell lines, including laryngeal carcinoma Hep-2 and hepatoma HepG-2 cells . This inhibition is both time- and dose-dependent.

• Optimal concentration effects: Interestingly, lower concentrations of RPL31 (0.33 μg/mL) showed better growth inhibition (44%) than higher concentrations when tested on Hep-2 cells, suggesting a complex mechanism of action .

• Research applications of RPL31 antibodies in cancer studies:

  • Expression profiling: Use RPL31 antibodies to examine expression levels across different cancer types and stages

  • Prognostic marker investigation: Correlate RPL31 expression with patient outcomes

  • Mechanism studies: Investigate how altered RPL31 expression affects cancer cell phenotypes

• Experimental approaches:

  • Tissue microarray analysis: Apply RPL31 antibodies to examine expression patterns across multiple tumor samples

  • Cellular response studies: Monitor RPL31 expression and localization changes in response to anticancer treatments

  • Co-localization with cancer markers: Combine RPL31 detection with markers of cell proliferation or apoptosis

How can I study potential post-translational modifications of RPL31?

Investigating post-translational modifications (PTMs) of RPL31 requires specialized experimental approaches:

• Detection strategies:

  • Immunoprecipitate RPL31 using specific antibodies followed by Western blotting with PTM-specific antibodies (e.g., phospho-, ubiquitin-, or SUMO-specific)

  • Use mass spectrometry analysis of immunoprecipitated RPL31 to identify and map specific modifications

• Sample preparation considerations:

  • Include appropriate phosphatase inhibitors for phosphorylation studies

  • Use denaturing conditions to preserve labile modifications

  • Consider crosslinking approaches to capture transient interactions

• Functional correlation:

  • Compare PTM patterns under different cellular conditions (stress, cell cycle phases, differentiation)

  • Assess the impact of PTMs on RPL31's incorporation into ribosomes

  • Investigate whether cancer cells show altered PTM patterns of RPL31

• Validation approaches:

  • Use lambda phosphatase treatment to confirm phosphorylation

  • Compare results under conditions known to induce specific modifications

How can RPL31 antibodies be used in conjunction with other techniques to study translation regulation?

Combining RPL31 antibodies with complementary techniques provides powerful approaches to study translation regulation:

• Polysome profiling:

  • Fractionate polysomes on sucrose gradients

  • Use RPL31 antibodies for Western blotting of fractions to track distribution

  • Correlate with specific mRNA populations to identify translation regulation patterns

• Proximity labeling approaches:

  • Use techniques like BioID or APEX2 with RPL31 as the bait protein

  • Identify proteins in close proximity to RPL31 during active translation

  • Validate findings using co-immunoprecipitation with RPL31 antibodies

• Translation inhibitor studies:

  • Treat cells with translation inhibitors (cycloheximide, puromycin, etc.)

  • Monitor changes in RPL31 localization or association with translation machinery

  • Assess impact on RPL31-containing ribosome complexes

• RNA-protein interaction analysis:

  • Perform RNA immunoprecipitation using RPL31 antibodies

  • Identify associated mRNAs to detect potential transcript-specific regulation

What approaches can be used to study the structural integration of RPL31 within the ribosome?

Understanding RPL31's position and function within the ribosome requires specialized techniques:

• Cryo-EM integration:

  • Use existing ribosome structural data to predict RPL31 interactions

  • Design validation experiments using RPL31 antibodies

  • Construct epitope-tagged RPL31 for structural studies

• Crosslinking studies:

  • Apply chemical crosslinkers to stabilize RPL31 interactions within the ribosome

  • Use RPL31 antibodies to immunoprecipitate crosslinked complexes

  • Identify interaction partners by mass spectrometry

• Mutational analysis:

  • Introduce mutations in RPL31 based on structural predictions

  • Assess the impact on ribosome assembly and function

  • Use RPL31 antibodies to track incorporation of mutant proteins

• Comparative analysis across species:

  • Use RPL31 antibodies with cross-species reactivity to examine conservation

  • Compare RPL31 integration and function in different model organisms

What methods can be used to study RPL31's role in the peptidyltransferase center?

As RPL31 is an important constituent of the peptidyltransferase center , specialized approaches can investigate its role:

• In vitro translation assays:

  • Deplete RPL31 from translation systems

  • Reconstitute with recombinant or purified RPL31

  • Measure impact on peptide bond formation efficiency

• Domain-specific antibodies:

  • Use antibodies targeting different RPL31 domains

  • Determine which domains are accessible in assembled ribosomes

  • Map functional regions through antibody interference studies

• Structural biology approaches:

  • Correlate RPL31 position with catalytic residues in the peptidyltransferase center

  • Design experiments to test proximity and functional relationships

  • Study the effects of RPL31 mutations on peptidyltransferase activity

What emerging research areas might benefit from RPL31 antibody applications?

Several cutting-edge research areas could be advanced using RPL31 antibodies:

• Specialized ribosomes and translational control:

  • Investigate whether RPL31 is differentially incorporated into ribosomes under specific conditions

  • Examine tissue-specific variants or modifications of RPL31

  • Study whether RPL31-containing ribosomes preferentially translate specific mRNA subsets

• Ribosome heterogeneity in disease:

  • Compare RPL31 incorporation patterns in normal versus disease states

  • Investigate potential diagnostic applications of RPL31 detection

  • Develop therapeutic approaches targeting RPL31-dependent processes

• Non-canonical functions:

  • Explore potential extraribosomal functions of RPL31

  • Investigate RPL31's role in cellular stress responses

  • Study RPL31 in non-translational ribonucleoprotein complexes

• Therapeutic development:

  • Further characterize the anticancer mechanisms of RPL31

  • Investigate RPL31 as a potential therapeutic target

  • Develop RPL31-based diagnostic approaches

How can recent technological advances enhance RPL31 antibody applications?

Emerging technologies that could be combined with RPL31 antibodies include:

• Super-resolution microscopy:

  • Visualize the precise localization of RPL31 within subcellular structures

  • Study dynamic changes in RPL31 distribution during cellular processes

  • Perform co-localization studies at nanometer resolution

• Single-cell proteomics:

  • Examine cell-to-cell variability in RPL31 expression

  • Correlate with single-cell transcriptomics data

  • Identify rare cell populations with altered RPL31 expression or localization

• CRISPR-based approaches:

  • Generate endogenously tagged RPL31 for live-cell imaging

  • Create RPL31 knockout or knockdown models

  • Perform precise domain mutations to study functional regions

• Computational biology integration:

  • Develop predictive models of RPL31 function based on structural data

  • Use machine learning to identify patterns in RPL31 expression across datasets

  • Design targeted experiments based on in silico predictions